The presence of CD4 + Th1 cells expressing IFN-γ in the TME is associated with beneficial clinical outcomes in patients with HER2 + breast cancer [16, 62] and other cancer types, including lung, colon, melanoma, and ovarian cancer [63]. Here, CD4 is linked to breast cancer.